BIIB vs. NBIX, AEP, RGEN, PNW, CRSP, POR, DNLI, GILD, ARGX, and BNTX
Should you be buying Biogen stock or one of its competitors? The main competitors of Biogen include Neurocrine Biosciences (NBIX), American Electric Power (AEP), Repligen (RGEN), Pinnacle West Capital (PNW), CRISPR Therapeutics (CRSP), Portland General Electric (POR), Denali Therapeutics (DNLI), Gilead Sciences (GILD), argenx (ARGX), and BioNTech (BNTX).
Biogen (NASDAQ:BIIB) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends, community ranking and earnings.
Biogen has a beta of -0.02, indicating that its stock price is 102% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500.
Biogen currently has a consensus price target of $293.88, indicating a potential upside of 40.68%. Neurocrine Biosciences has a consensus price target of $142.38, indicating a potential upside of 4.70%. Given Biogen's higher probable upside, equities research analysts clearly believe Biogen is more favorable than Neurocrine Biosciences.
In the previous week, Biogen had 40 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 74 mentions for Biogen and 34 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 0.66 beat Biogen's score of 0.52 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.
Biogen has higher revenue and earnings than Neurocrine Biosciences. Biogen is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.
87.9% of Biogen shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 0.6% of Biogen shares are owned by insiders. Comparatively, 4.4% of Neurocrine Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Neurocrine Biosciences has a net margin of 13.23% compared to Biogen's net margin of 12.07%. Biogen's return on equity of 14.83% beat Neurocrine Biosciences' return on equity.
Biogen received 797 more outperform votes than Neurocrine Biosciences when rated by MarketBeat users. However, 77.63% of users gave Neurocrine Biosciences an outperform vote while only 71.86% of users gave Biogen an outperform vote.
Summary
Neurocrine Biosciences beats Biogen on 10 of the 18 factors compared between the two stocks.
Get Biogen News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BIIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
